Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 83

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 83
---
 |    (863,550 | ) |     |                   | (100.0 | )% |
| Interest income (expense), net                                         |     |                          |      14,626 |   |     |                                         |    (26,606 | ) |     |            |      41,232 |   |     |                   |  155.0 | %  |
| Total other income (expense), net                                      |     |                          |    (848,924 | ) |     |                                         |  4,951,959 |   |     |            |  (5,800,883 | ) |     |                   | (117.1 | )% |
| Net loss                                                               |     |                          | (10,523,246 | ) |     |                                         | (4,748,348 | ) |     |            |  (5,774,898 | ) |     |                   |  121.6 | %  |
| Deemed dividend on Series A, B and C Preferred Stock                   |     |                          | (24,964,518 | ) |     |                                         |          - |   |     |            | (24,964,518 | ) |     |                   |    100 | %  |
| Deemed dividend related to Series C Common Warrants                    |     |                          |     (84,083 | ) |     |                                         |          - |   |     |            |     (84,083 | ) |     |                   |    100 | %  |
| Net loss attributable to common stockholders                           |     | $                        | (35,571,847 | ) |     | $                                       | (4,748,348 | ) |     | $          | (30,823,499 | ) |     |                   |  649.1 | %  |

Research and Development Expenses

Research and
development expenses were $5,662,000 for the six months ended June 30, 2025 as compared to $4,383,000 for the six months ended June
30, 2024, reflecting an increase of $1,279,000. The increase was primarily attributable to an increase in clinical expenses of
$2,362,000, and an increase in scientific consulting fees of $496,000. In the first quarter of 2025, we began clinical trials
related to the IND for CER-1236. This increase was primarily offset by a decrease in lab